AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05520658
Drug: 5 fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 fluorouracil mixed with1ml of 2% lignocaine and epinephrine one session every 2 weeks for maximum 6 sessions .
Trial: NCT06468098
Drug: IBI363 + Investigator's Choice SOC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this group, patients will receive IBI363 and Investigator's Choice SOC
Trial: NCT06409299
Drug: Azithromycin 40 MG/ML
RxNorm normalized name: azithromycin 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance Antibiotic treatment
Trial: NCT04976309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT06186622
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06186622
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally.
Trial: NCT06186622
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05531708
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: D-7 and D-6: Cyclophosphamide (60 mg/kg/day) will be administered intravenously for 2 days.
Trial: NCT05079126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV Bolus
Trial: NCT04427904
Drug: Bupivacaine 0.5% with 1:200 000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% with 1:200 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
Trial: NCT04427904
Drug: Lidocaine 2% with 1:100 000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% with 1:100 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
Trial: NCT06186895
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl (1 μg/kg) that was given intravenously slowly over 60 seconds before induction of anesthesia as a loading dose. Following intubation, a continuous infusion of fentanyl was administered at a rate of 1μg/kg/hr. The infusion was discontinued upon the removal of the trocars.
Trial: NCT01168375
Drug: conventional therapy plus umbilical cord serum eye drop
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours plus umbilical cord serum eye drop 20% every 4 hours
Trial: NCT01168375
Drug: conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours
Trial: NCT04857606
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo administered as a subcutaneous injection.
Trial: NCT05951309
Drug: inofolic combi
RxNorm normalized name: NexGard Combo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in this group were given inofolic combi once a day for 12-16 weeks
Trial: NCT04728724
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment stage: Sintilimab 200mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (Non-squamus: Carboplatin AUC 5 + Pemetrexed 500mg/m2; Squamous: Carboplatin AUC 5 + Gemcitabine 1000mg/m2 or Paclitaxel 200mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines.
Trial: NCT05399069
Drug: VGR-R01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene Replacement Therapy
Trial: NCT05323136
Drug: MT1002 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose: 0.90 mg/kg initial loading dose (bolus intravenous injection) over 5 minutes + 1.8 mg/kg/hour (infusion) for 4 hours.
Trial: NCT05355298
Drug: AMP945 RP2D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B will determine the efficacy of the AMP945 priming regimen at the recommended phase 2 dose (RP2D) determined in Part A.
Trial: NCT06514222
Drug: Paracetamol and Ibuprofen. The combination of the Paracetamol and Ibuprofen will be given together every 8 hours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1- The patient will receive 400mg ibuprofen plus 1000mg Paracetamol simultaneously every 8 hours for two days.
Trial: NCT06514222
Drug: Paracetamol and Ibuprofen. The combination of the Paracetamol and Ibuprofen will be given alternatively every four hours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2- The patient will receive 400mg ibuprofen and 1000mg Paracetamol at 4 hours in intervals for two days. With a total of 3 doses of ibuprofen and 3 doses of paracetamol per day
Trial: NCT06160232
Drug: Active placebo (low dose of psilocybin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-assisted therapy
Trial: NCT06289933
Drug: BR3005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone, Once a day
Trial: NCT06289933
Drug: BR3005-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone, Once a day
Trial: NCT06289933
Drug: BR3005-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone, Once a day
Trial: NCT04874350
Drug: LPCN 1148
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPCN 1148 is an oral capsule product containing an ester prodrug of bioidentical testosterone, designed to enable absorption via intestinal lymphatics.
Trial: NCT04874350
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral matching placebo capsule
Trial: NCT04771351
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluent solution
Trial: NCT04921943
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulizing with 7% hypertonic saline twice daily for 12 weeks.
Trial: NCT04921943
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of care
Trial: NCT04730765
Drug: antibiotic therapy (medical Control Group)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatement for 10 days by oral or intravenous administration
Trial: NCT05222399
Drug: LY3871801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05672888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (given as two placebo tablets) administered orally BID with best available treatment.
Trial: NCT00238160
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06314334
Drug: P-GemOx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. pegaspargase 2000U/m\^2, capped at 3750U on day 1, intramuscular;~2. gemcitabine 1.0g/m\^2 on day 1 and day 8, intravenous drip;~3. oxaliplatin 130mg/m\^2 on day 1, intravenous drip
Trial: NCT05620160
Drug: RAY1216
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAY1216（tablet）
Trial: NCT05620160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo （tablet）
Trial: NCT05835505
Drug: BRS201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.
Trial: NCT05835505
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.
Trial: NCT04816487
Drug: Potassium Iodide or Glutathione
RxNorm normalized name: Potassium Iodide
DrugBank: Potassium Iodide (DB06715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will receive either Glutathione or Potassium iodide
Trial: NCT06244004
Drug: Antiandrogen Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo SOC ADT
Trial: NCT01431586
Drug: JDtic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The planned JDTic dose levels to be evaluated are 1 mg, 3 mg, and 10 mg; however, the actual dose levels evaluated may be different, and/or additional dose levels may be added by protocol amendment, depending on the safety and PK results of the lower doses.~Subjects will be admitted to the clinic the day before dosing and will be confined to the clinic for 6 nights, with safety and PK evaluations and assessments lasting approximately 125 hours following administration of study drug.
Trial: NCT05126121
Drug: three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,levofloxacin,tinidazole,metronidazol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,tinidazole,metronidazol
Trial: NCT06244004
Drug: Cytotoxic Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive SOC cytotoxic chemotherapy
Trial: NCT06258265
Drug: TAK-279 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-279 matching placebo capsule.
Trial: NCT05231694
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.
Trial: NCT06405490
Drug: Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Use the above medications on a regular basis
Trial: NCT06449859
Drug: TQC2938 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.
Trial: NCT06449859
Drug: TQC2938 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQC2938 Placebo is a placebo comparator
Trial: NCT05696483
Drug: OLX-07010 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 and 75 mg capsules
Trial: NCT05452187
Drug: Assess the effectiveness and safety of DAAs in patients with IBD.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variables evaluated: age, gender, location, extent, phenotype, and activity of IBD, treatments, anti-HCV and viral load, DAA treatment and duration, fibrosis and hepatic decompensation and adverse effects (AE).
Trial: NCT05452187
Drug: Evaluate the interaction of DAAs with IBD drugs, particularly immunosuppressants and/or biologics.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variables evaluated: Interactions.
Trial: NCT04857840
Drug: Firibastat (QGC001) Period 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg (2 x 500 mg) tablets QD per Os
Trial: NCT05279352
Drug: FBR-002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration on D1 and D3
Trial: NCT05279352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration on D1 and D3
Trial: NCT04940741
Drug: VER-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standardised cannabis extract (containing 21 mg THC per gram drug product)
Trial: NCT05135468
Drug: CU-40102 Spray
RxNorm normalized name: Cu 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical application, 1\~4 sprays each time, once daily
Trial: NCT05445440
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT05445440
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT05752175
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT04884295
Drug: XVR011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of XVR011 via intravenous (IV) infusion
Trial: NCT05801367
Drug: Allium Sativum Oil
RxNorm normalized name: Allium sativum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allium sativum oil will be used as non-vital pulpotomy medicament compared with Formocresol (which is gold standard)
Trial: NCT05098249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participant takes wo capsules Placebo orally three times a day over 30 days beginning the day of Ferinject administration.
Trial: NCT05825365
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Transfer to selumetinib on REiNS-defined PD)
Trial: NCT05000216
Drug: Continue IS (MTX)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.
Trial: NCT04969172
Drug: Exosomes overexpressing CD24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The suggested therapeutic agent here is based on an existing therapeutic platform that uses exosomes that were engineered to overexpress CD24 that can directly suppress the cytokine storm. The exosomes will be isolated and purified from human embryonic kidney T-REx™-293 cells that constitutively express high levels of human CD24.
Trial: NCT05474924
Drug: Prednisolone tablets
RxNorm normalized name: Prednisolone Tablets
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral prednisolone tablet dosage 1 mg/kg/d tapered daily for 2 weeks.
Trial: NCT05264870
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: treatment of postspinal hypotension
Trial: NCT05747664
Drug: DWP16001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3mg
Trial: NCT04441047
Drug: AlloStim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Living, activated allogeneic Th1-like memory immune cells
Trial: NCT06169202
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 orally twice daily, D1-14, repeated every 3 weeks.
Trial: NCT06079788
Drug: Adrenocorticotrophic Hormone
RxNorm normalized name: Adrenocorticotrophic hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients in complete remission, ACTH is given at a prednisone dose of 1.5-2mg/kg qod or 0.75-1mg/kg qd. ACTH 2 IU/kg/ day, qd,（the maximum dose ≤ 50 IU）, 28 days of continuous use for 5 days， for 24 weeks.~Prednisone: 5mg；Oral tablets; 1.5-2 mg/kg, qod or 0.75-1mg/kg/day,qd, then gradually taper the steroid by 0.25mg/kg qod or 0.125mg/kg qd every 4 weeks.If stable, taper to 5mg qod (body surface area \> 1.0m2) and 2.5mg qod (body surface area \< 1.0m2) and maintain the dose until study completion.
Trial: NCT06079788
Drug: Steroid
RxNorm normalized name: Steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients in complete remission, Prednisone: 5mg；Oral tablets; 1.5-2 mg/kg, qod or 0.75-1mg/kg/day,qd, then gradually taper the steroid by 0.25mg/kg qod or 0.125mg/kg qd every 4 weeks. If stable, taper to 5mg qod (body surface area \> 1.0m2) and 2.5mg qod (body surface area \< 1.0m2) and maintain the dose until study completion.
Trial: NCT05892614
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion over approximately 60 minutes every 4 weeks
Trial: NCT05045534
Drug: Comparison of TB-840 treatment with Placebo
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose or Multiple Dose of TB-840 treatment
Trial: NCT04662567
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: compare the postoperative pain 1 hour and \~24h post surgery
Trial: NCT05917912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrogel bottle of placebo , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks
Trial: NCT05987358
Drug: TQB3454 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3454 is a selective IDH1 mutant enzyme inhibitor.
Trial: NCT05987358
Drug: TQB3454 tablets matching placebo
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets without active substance.
Trial: NCT04273607
Drug: Subcutaneous Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention group will receive prophylactic heparin instead of standard of care therapeutic intravenous heparin
Trial: NCT05427981
Drug: Belbuca Buccal Product
RxNorm normalized name: Belbuca Buccal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine Buccal Films
Trial: NCT04985929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical-grade placebo pill, over-encapsulated to be identical in appearance to the sildenafil intervention.
Trial: NCT04531592
Drug: Isotonic saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline solution consisting of 0.9% sodium chloride in the volume of 300 ml for administration
Trial: NCT03398252
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive a placebo for doxazosin XL.
Trial: NCT05631405
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients treated with placebo
Trial: NCT04608981
Drug: Prednisolone 30 mg
RxNorm normalized name: prednisolone 30 MG
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Steroidal anti-inflammatory drug as a preoperative medication
Trial: NCT04608981
Drug: Diclofenac Potassium 50mg Tab
RxNorm normalized name: DICLOFENAC POTASSIUM 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drug as a preoperative medication
Trial: NCT04608981
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch
Trial: NCT05465668
Drug: DWP16001 Drug A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP16001 Drug A
Trial: NCT05465668
Drug: DWP16001 Drug C
RxNorm normalized name: Synovex C Drug Implant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP16001 Drug C
Trial: NCT05386953
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received normal saline as a maintenance crystalloid during liver transplantation surgery.
Trial: NCT05386953
Drug: Balanced crystalloid solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received balanced crystalloids such as lactated Ringer's solution or Plasma solution as a maintenance crystalloid during liver transplantation surgery.
Trial: NCT05242029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo in a clinical setting.
Trial: NCT05914155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer placebo IV infusion every two weeks for two doses in double-blind phase.
Trial: NCT05613491
Drug: Intranasal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Put 0.9% sodium chloride into nasal special drug delivery device.Before anesthesia induction, give the first equal volume saline nasal spray, once per hour, 20 IU each time, until the end of the operation
Trial: NCT04580238
Drug: Botox 200 UNT Injection
RxNorm normalized name: Botox 200 UNT Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Protocol:~Botox 200 IU vials for 40 patients for the duration of study (4 treatment cycles); Treatment will be based on the PREEMPT study full treatment (standard of care) and follow the pain protocol to a total of 195 IU in standard injection sites
Trial: NCT06243198
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (SC)
Trial: NCT04913610
Drug: Placebo for ABBV-4083
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT05390749
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: methotrexate 3.5g/m2 civ d1/cycle5-6
Trial: NCT00000703
Drug: Doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06206824
Drug: Leucettinib-21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm's description.
Trial: NCT00000703
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00000703
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00000703
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04892641
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for 250 mg epetraborole hydrochloride tablets for oral administration